Share Name Share Symbol Market Type Share ISIN Share Description
Berkeley Scott Group LSE:BGP London Ordinary Share GB00B03W5P29 ORD 2P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 22.59p 0 06:30:09
Bid Price Offer Price High Price Low Price Open Price
0.00p 0.00p - - -
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
18.0 -0.4 -4.5 - 5.15

Berkeley Scott (BGP) Latest News

Real-Time news about Berkeley Scot (London Stock Exchange): 0 recent articles
More Berkeley Scott News
Berkeley Scott Takeover Rumours

Berkeley Scott (BGP) Share Charts

1 Year Berkeley Scott Chart

1 Year Berkeley Scott Chart

1 Month Berkeley Scott Chart

1 Month Berkeley Scott Chart

Intraday Berkeley Scott Chart

Intraday Berkeley Scott Chart

Berkeley Scott (BGP) Discussions and Chat

Berkeley Scott Forums and Chat

Date Time Title Posts
25/1/200808:57Berkeley Scott Group46
10/4/200415:50BIOGLAN PHARMA..121
04/5/200313:31Employees shafted36
03/5/200221:49WATCH THIS FLY!!!!!!!!32
26/4/200210:23Adminstration Process Begins35

Add a New Thread

Berkeley Scott (BGP) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Berkeley Scott trades in real-time

Berkeley Scott (BGP) Top Chat Posts

sjc: LONDON (AFX) - A Bioglan Pharma PLC share issue would probably create some share price weakness, but this would represent a strong buying opportunity, according to WestLB Panmure analyst Emma Palmer. A press report that Bioglan's institutional shareholders are putting pressure on the company to make a 200 mln stg share issue to fund the acquisition of Bristol-Myers Squibb's skin-care arm saw Bioglan's shares fall to 390 pence at the outset. By 11.04 am, however, the stock had rallied to show a gain of a 1/2 at 398 as dealers adopted a more positive stance on a possible share issue. The 484 mln stg acquisition would give the company a much bigger presence in the US and turn it into one of the UK's largest independent drugs companies. The company's plan to finance the deal via increased borrowing, however, has triggered worries about the resulting high level of debt. Since the deal has not yet been finalised -- and there are no guarantees that it will happen -- there are no details and any comments made are speculative, said Palmer. However, since the number of shares needed for the suggested 200 mln usd upfront payment would increase issued capital by a third at present levels, the analyst expects there to be some price weakness and believes that this represents a strong buying opportunity. An initial payment of 200 mln usd would increase gearing to 167 pct from the current level of 60 pct. The press rumours suggest that institutional investors are unhappy with this level of gearing and are instead pressurising the company to issue new shares. fjb/jsa For more information and to contact AFX: and Bioglan Pharma(BGP) GB0004342670 C(p) -1.25 C(%) -19.231 C 5.25 B 5.0 O 5.5 H 6.25 L 4.75 Op 5.75 V 3,238,599 T close A GOOD CALL EMMA.
paul dsp: Think about how much you would be willing to give shareholders if you represented somebody with money to spare to take this company off their hands. It won't be 0 pence, I shouldn't think, but it wont be very much either. At the moment, it is dying on its own, and any offer will be pitched to persuade Terry Sadler, and any other major holders, to walk away and not make a fuss. It is possible that a profit on the current share price can be made (especially as it has dropped 20% during today), but it is most likely that the offer will come in around, or maybe a little under the open market price. For a company that makes a good case study of this sort or situation, look at the last few months for Cedar (CED) Good luck all. And remember, nobody here actually knows what will happen, they can only speculate. Paul DSP
glynwiseman: Surely this deal should be good for the share price but it has dropped 19% today - Have I missed something here? and can anyone explain why the price has dropped so much today?
wetdream: Presumably with Goldman Sachs' guidance and the OK of the banks, it looks like BGP is making a tactical withdrawal from the US, transferring marketing rights to Quintiles, and paying down their debt. Since most of their current revenues were in Europe in any case that doesn't seem too bad, considering their dire condition. However, it must severely hamper their plans for global domination of the dermatological market! But what does it all mean for the BGP share price?! No doubt Sadler will (correctly) take the biggest hit. Any views? Worth a punt @ 7p?
mali7: RocketMan! I never ramp or deramp, and those buying without their own research can ... Anyway I have seen you ramping and deramping without evidence! What I meant is that when institions get more confident about BGP then the share price will start rocketing up, because of their buyings. Until now the share price has moved very slowly, + - 0.5p, and considering the amount shares bought it's only small amounts. But when instituions start buying it will go up quicker, which means those waiting have to pay a higher price for the share as the demand increases.
catapuss: That is obviously how Bioglan have got themselves into such debt. Apply the same criteria to their products as their share price. Don't they know that the way to drastically increase sales and revenue is to charge much higher prices? Nobody wants to buy when the price is at an all time low, they want to see it increase 50% first, just to show it was worth what they were charging in the first place!
mattj123: Any idea as to why the sells today have not shifted the BGP price downwards?
saturn5: Happy New Year to all BGP holders The way I see it SKP will be tied into BGP and the share price of SKP is on the up. Thus I do not think all is lost with BGP. Elan is a tip in some papers You have to be in it to win it. Best of luck
redmanski: BGP price target £6
custardpie: I think it is a case of out of the fryingpan and into the fire, by pushing through the deal wether funded by debt or equity will have a downward effect on the share price as we have all ready seen(althought the effect could well be factored into the price by now) By withdrawing from the deal this will just go to highlite the indecisevnes of management, the rifts that are there due to Sadlers one man stand against all the advice of his own board and brokers ,all this will not inspire much confidence in the city and imho this has not been factored into the current share price.We all know what happens when deals collapse in the city.I hope though this will be a short term reaction and hopefully BGP product line will help them,especially as they look at the second part of the year as being better than the first.
Berkeley Scott share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20180320 02:31:35